AMGEN Inc

NASDAQ: AMGN
$281.79
-$14.14 (-4.8%)
Real Time Data Delayed 15 Min.

AMGN Articles

The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The June 28 short interest data has been compared with the previous report, and short interest in most...
The June 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data have been compared with the previous report, and short interest in most...
Amgen is the largest of all biotechs now, and it is being deemed an "ASCO winner" for cancer and oncology news. At least, that is the view of Credit Suisse.
The May 15 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Despite the wearing down of hepatitis C drugs and the political climate targeting drug prices, this analyst sees stabilization and predictability in the base businesses of two key biotech leaders.
The top analyst upgrades, downgrades and initiations seen on Thursday included AK Steel, Amgen, Booking, Chubb, Chipotle Mexican Grill, Expedia, Gilead Sciences, Goodyear, Philip Morris, Target and...
24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new ideas for investors and traders alike. Some of these analyst reports cover stocks to buy, while others cover...
The April 30 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The April 15 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how much they are lagging...
Jefferies did a deep dive into the health care sector, looking for underperforming stocks that could hold some solid value going forward.
The March 29 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.